Gland Pharma has received Establishment Inspection Report (EIR) from the USFDA for its Pashamylaram facility at Hyderabad. USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 25, 2024 and August 02, 2024. The said inspection was concluded with three 483 Observations.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.